HBM Holdings Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Jingsong Wang

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	7.8yrs
Participación del CEO	8.4%
Permanencia media de la dirección	1.4yrs
Promedio de permanencia en la Junta Directiva	3.8yrs

Actualizaciones recientes de la dirección

Recent updates

Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper

Apr 12

HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Jan 01

We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate

Feb 08

HBM Holdings (HKG:2142) Is In A Strong Position To Grow Its Business

May 30

Revenue Downgrade: Here's What Analysts Forecast For HBM Holdings Limited (HKG:2142)

Apr 07

Here's What Analysts Are Forecasting For HBM Holdings Limited (HKG:2142) After Its Full-Year Results

Mar 31

What Type Of Shareholders Own The Most Number of HBM Holdings Limited (HKG:2142) Shares?

Mar 10

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jingsong Wang en comparación con los beneficios de HBM Holdings?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	US$23m
Sep 30 2023	n/a	n/a	-US$19m
Jun 30 2023	n/a	n/a	-US$61m
Mar 31 2023	n/a	n/a	-US$99m
Dec 31 2022	n/a	n/a	-US$137m
Sep 30 2022	n/a	n/a	-US$143m
Jun 30 2022	n/a	n/a	-US$149m
Mar 31 2022	n/a	n/a	-US$144m
Dec 31 2021	US$13m	US$13m	-US$138m
Sep 30 2021	n/a	n/a	-US$224m
Jun 30 2021	n/a	n/a	-US$310m
Mar 31 2021	n/a	n/a	-US$303m
Dec 31 2020	US$21m	US$654k	-US$296m

Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Jingsong es razonable en comparación con empresas de tamaño similar en el mercado Hong Kong.

Compensación vs. Ingresos: La compensación de Jingsong ha sido consistente con los resultados de la empresa en el último año.

CEO

Jingsong Wang (58 yo)

7.8yrs

Permanencia

US$13,267,000

Compensación

Dr. Jingsong Wang M.D., Ph D., serves as Chairman of Board of Directors of HBM Alpha Therapeutics, Inc. He has been Chief Executive Officer of HBM Holdings Limited and Harbour BioMed Shanghai Co., Ltd. sin...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jingsong Wang	Founder	no data	US$13.27m	8.43% $ 84.0m
Weihao Xu	CFO, Chief Business Officer and Global Head of Business & Corporate Development	2.4yrs	sin datos	sin datos
Yiping Rong	Chief Scientific Officer & Executive Director	1.4yrs	sin datos	0.028% $ 277.4k
Bruce Zhang	Head of Legal	no data	sin datos	sin datos
Peter Moesta	Member of Scientific Advisory Board & Chief CMC Advisor	no data	sin datos	sin datos
Xiaolu Tao	Chief Development Officer	no data	sin datos	sin datos
Steve Arkinstall	Chief Scientific Advisor	less than a year	sin datos	sin datos
Wing Yat Lui	Company Secretary	no data	sin datos	sin datos

1.4yrs

Permanencia media

45yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2142 no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jingsong Wang	Founder	7.8yrs	US$13.27m	8.43% $ 84.0m
Yiping Rong	Chief Scientific Officer & Executive Director	2yrs	sin datos	0.028% $ 277.4k
Peter Moesta	Member of Scientific Advisory Board & Chief CMC Advisor	no data	sin datos	sin datos
Robert Kamen	Independent Non-Executive Director & Member of Scientific Advisory Board	7.4yrs	US$50.00k	0.36% $ 3.6m
Alexander A. Zukiwski	Member of Scientific Advisory Board	2yrs	sin datos	sin datos
Xiaoping Ye	Independent Non-Executive Director	3.5yrs	US$50.00k	sin datos
Jon Marc Wigginton	Member of Scientific Advisory Board	3.9yrs	sin datos	sin datos
Robert Kramer	Member of Scientific Advisory Board	7.4yrs	sin datos	sin datos
Ka Chi Yau	Independent Non-Executive Director	2.9yrs	US$28.00k	sin datos
Frank Grosveld	Member of Scientific Advisory Board	7.4yrs	sin datos	sin datos
Weiwei Chen	Senior Business Adviser & Non-Executive Director	3.5yrs	US$22.00k	sin datos
Zhigang Tian	Member of Scientific Advisory Board	3.8yrs	sin datos	sin datos

3.8yrs

Permanencia media

60.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 2142 se considera experimentada (3.7 años de antigüedad promedio).

HBM Holdings Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

HBM Holdings Limited, Annual General Meeting, Jun 06, 2024

HBM Holdings Limited Announces Executive Changes

Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director

HBM Holdings Limited Announces Board Changes

HBM Holdings Limited Appoints Steve Arkinstall as Chief Scientific Advisor of Nona Biosciences

Less than half of directors are independent

Recent updates

New minor risk - Market cap size

Investor sentiment deteriorates as stock falls 16%

Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper

HBM Holdings Limited, Annual General Meeting, Jun 06, 2024

Full year 2023 earnings released: EPS: US$0.03 (vs US$0.19 loss in FY 2022)

HBM Holdings Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Harbour BioMed Announces IND Clearance for HBM9027 in the U.S

HBM Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2023

HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement

HBM Holdings Limited Announces Executive Changes

New major risk - Revenue and earnings growth

Forecast to breakeven in 2023

Consensus EPS estimates upgraded to US$0.05 loss

First half 2023 earnings released: EPS: US$0.004 (vs US$0.10 loss in 1H 2022)

Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors

HBM Holdings Limited to Report First Half, 2023 Results on Aug 28, 2023

Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director

New minor risk - Share price stability

HBM Holdings Limited Announces Board Changes

National Medical Products Administration of China Accepts Biologics License Application for HBM Holdings Limited's Batoclimab for Treatment of gMG

HBM Holdings Limited Appoints Steve Arkinstall as Chief Scientific Advisor of Nona Biosciences

Harbour BioMed Announces First Patient Dosed in Phase I Study of First-In-Class Anti-B7H7 (HHLA2) Antibody HBM1020

Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023

Consensus revenue estimates increase by 28%

Consensus estimates of losses per share improve by 36%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Hbm Holdings Limited Announces Food and Drug Administration of the United States Investigational New Drug Clearance for HBM1020 Clinical Trial Initiation

Hbm Holdings Limited Announces Results from Phase I Clinical Trial of Porustobart (Hbm4003)In Combination with Toripalimab in Advanced Melanoma

WuXi Vaccines (Hong Kong) Limited entered into an agreement to acquire Manufacturing facility in Suzhou from HBM Holdings Limited (SEHK:2142).

Less than half of directors are independent

HBM Holdings Limited Appoints Mr. Weihao Xu as Chief Business Officer

Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody in the United States

Hbm Holdings Limited Announces Closing the Study of Phase III Clinical Trial of Tanfanercept (Hbm9036)

Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody

Consensus forecasts updated

First half 2022 earnings released: US$0.10 loss per share (vs US$0.084 loss in 1H 2021)

Hbm Holdings Limited Announces Completion of First Dosing of Last Patient with Hbm4003 Phase Ib Trial

Harbour BioMed Announces the Preclinical Results of Porustobart

HBM Holdings Limited to Report First Half, 2022 Results on Aug 31, 2022

Harbour BioMed Announces IND Clearance for B7H4x4-1BB Bispecific Antibody by the U.S. Food and Drug Administration

HBM Holdings Limited Announces IND Approval for Commencement of Phase I Trial of B7H4X4-1BB Bispecific Antibody in China

Hbm Holdings Limited Announces Data Release of Next-Gen Ctla-4 Antibody At Asco 2022

HBM Holdings Limited Announces That Dosing of First Patient in Phase I Trial of B7h4x4-1Bb Bispecific Antibody Hbm7008 Has Been Completed

Consensus forecasts updated

Hbm Holdings Limited Announces Data Release Forecast of Hbm4003 At ASCO 2022

HBM Holdings Limited Announces Board Changes

Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board

Less than half of directors are independent

Harbour BioMed Appoints Humphrey Gardner as Chief Medical Officer

Consensus revenue estimates increase by 302%

Harbour BioMed Announces Approval for Phase I Trial of B7H4x4-1BB Bispecific Antibody in Australia

HBM Holdings Limited Announces Approval of Investigational New Drug Application for HBM9378 by National Medical Products Administration of the People's Republic of China

We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate

HBM Holdings Limited Announces Completion of First Interim Analysis of Phase III Clinical Trial of Tanfanercept (HBM9036)

Founder recently bought HK$1.0m worth of stock

HBM Holdings Limited Announces Completion of First Dosing of First Patient with Two HBM4003 Phase I Trials

HBM Holdings Limited Announces Completion of First Dosing of First Patient with Batoclimab (Hbm9161) Phase III Trial for Treatment of Generalized Myasthenia Gravis

Harbour Biomed Announces Phase I Study Positive Results on Next-Generation Anti-CTLA-4 Antibody HBM4003

HBM Holdings Limited Announces Chinese Regulatory Approval of Two Ind Applications for Next-Generation Anti-Ctla-4 Antibody Hbm4003

First half 2021 earnings released: US$0.084 loss per share (vs US$0.39 loss in 1H 2020)

HBM Holdings Limited Receives National Medical Products Administration of the People's Republic of China Approval of Investigational New Drug Application to Begin Phase II Clinical Trial of HBM9161 in Chronic Inflammatory Demyelinating Polyneuropathy

Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC

HBM Holdings Limited Provides Update on Ongoing Clinical Studies Forbatoclimab (HBM9161)

HBM Holdings (HKG:2142) Is In A Strong Position To Grow Its Business

Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody

Executive Director, Chief Strategy Officer & Head of U.S. Operations has left the company

Full year 2020 earnings released: US$1.69 loss per share (vs US$0.57 loss in FY 2019)

Revenue Downgrade: Here's What Analysts Forecast For HBM Holdings Limited (HKG:2142)

Consensus forecasts updated